Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.31 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.31 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11179160 | 1.00 | HRH3 (0.39) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL10846104 | 0.98 | HRH3 (0.36) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL11889487 | 0.88 | HRH3 (0.46) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL5498786 | 0.78 | IDO1 (0.34) | — | |
| SCHEMBL5248220 | 0.77 | FDPS (0.31) | — | |
| SCHEMBL4508119 | 0.76 | POLB (0.38) | POLBSMN1; SMN2 | |
| SCHEMBL646006 | 0.76 | KEAP1 (0.39) | ALDH1A1POLBTSHRACHESMN1; SMN2 | |
| SCHEMBL2099926 | 0.75 | HRH3 (0.40) | HRH3LMNAALDH1A1MAPTTSHR | |
| SCHEMBL6872232 | 0.74 | HRH3 (0.42) | HRH3LMNAALDH1A1MAPTPOLB | |
| SCHEMBL6872234 | 0.74 | HRH3 (0.42) | HRH3LMNAALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | HRH3 961/4885LMNA 422/4885ALDH1A1 1113/4885 |
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | HRH3 27/4885LMNA 3652/4885ALDH1A1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.